Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 23 of 23 entries
View as:

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04044768 Org: User:
Start: 08/13/19 End: 04/01/38 Due: 04/01/39

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06048705 Org: User:
Start: 03/09/21 End: 06/08/23 Due: 06/08/24

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05943990 Org: User:
Start: 12/21/20 End: 10/24/22 Due: 10/24/23

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants with NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT06703346 Org: User:
Start: 12/31/19 End: 07/31/26 Due: 07/31/27

AFPᶜ³³²T in Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT03132792 Org: User:
Start: 05/08/17 End: 07/07/25 Due: 07/07/26

CT Antigen TCR-Engineered T Cells for Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01892293 Org: User:
Start: 10/15/13 End: 04/09/18 Due: 04/09/19

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02989064 Org: User:
Start: 10/31/16 End: 06/04/20 Due: 06/04/21

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Phase: N/A Priority: Normal
NCT ID: NCT04752358 Org: User:
Start: 09/15/21 End: 12/15/23 Due: 12/15/24

CT Antigen TCR-redirected T Cells for Ovarian Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT01567891 Org: User:
Start: 07/09/13 End: 06/06/17 Due: 06/06/18

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Phase: N/A Priority: Normal
NCT ID: NCT03391778 Org: User:
Start: 04/09/18 End: 04/01/32 Due: 04/01/33

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05993299 Org: User:
Start: 12/31/19 End: 07/01/25 Due: 07/01/26

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Phase: N/A Priority: Normal
NCT ID: NCT03132922 Org: User:
Start: 05/15/17 End: 09/30/32 Due: 09/30/33

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01350401 Org: User:
Start: 06/01/11 End: 03/01/18 Due: 03/01/19

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03967223 Org: User:
Start: 12/31/19 End: 07/31/26 Due: 07/31/27

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04408898 Org: User:
Start: 07/02/20 End: 12/31/21 Due: 12/31/22

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Phase: N/A Priority: Normal
NCT ID: NCT04044859 Org: User:
Start: 08/20/19 End: 04/30/37 Due: 04/30/38

Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel

Phase: N/A Priority: Normal
NCT ID: NCT06617572 Org: User:
Start: - End: - Due: -

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Phase: N/A Priority: Normal
NCT ID: NCT02636855 Org: User:
Start: 12/31/15 End: 06/28/24 Due: 06/28/25

ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Phase: N/A Priority: Normal
NCT ID: NCT05601752 Org: User:
Start: 06/26/23 End: 08/12/26 Due: 08/12/27

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Phase: N/A Priority: Normal
NCT ID: NCT03391791 Org: User:
Start: 02/28/18 End: 07/24/18 Due: 07/24/19

SPEARHEAD-3 Pediatric Study

Phase: N/A Priority: Normal
NCT ID: NCT05642455 Org: User:
Start: 09/01/23 End: 07/30/38 Due: 07/30/39

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04526509 Org: User:
Start: 12/21/20 End: 06/08/23 Due: 06/08/24

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02592577 Org: User:
Start: 11/30/15 End: 03/17/21 Due: 03/17/22